Pharmacyclics, Inc.

Principia Biopharma Inc.

Corvus Pharmaceuticals, Inc.

Pharmacylics, Inc.

Angel Pharmaceutical Co., Ltd.

Principia Biopharmac, Inc.

Janssen Pharmaceutica Nv

Erik J Verner

Lee Honigberg

Zhengying Pan

Joseph J Buggy

David J Loury

Wei Yu Chen

Sriram Balasubramanian

Kenneth Albert Brameld

Tarak D Mody

Martin Sendzik

James Robinson

Chitra Baskaran

Tim Owens

Norbert Purro

Chang-Sun Lee

Vincent W F Tai

Ryan Hudson

Anne-Marie Beausoleil

Hon Chung Hui

Richard A Miller

David Michael Goldstein

Mark Stephen Smyth

Erick A Goldman

Andras Horvath

Zhihong Li

Stéphane Depil

Wei Chen

Heleen Scheerens

Ioana Kloos

Erin Kathleen Bradley

Lubov Konstantinovna Filonova

Wenchen Luo

Shyr Jiann Li

Philip Pye

Cyril Benhaim

Lee Honingberg

Heleen Schereens

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Quinolone derivatives as fibroblast growth factor receptor inhibitors

Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.

Compounds and methods for modulating Bruton's Tyrosine Kinase

Disclosed herein, inter alia, are certain substituted thieno[3,2-b]pyrimidine compositions and methods for modulating Adenosine Receptors, for example, having the formula: 

Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor

The present disclosure provides compounds of Formula (IA), such as, e.g., and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors

Compounds and methods for modulating bruton's tyrosine kinase

Quinolone derivatives as FGFR inhibitors

The present disclosure provides compounds of Formula (IA), such as, e.g., 

Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Formulations of histone deacetylase inhibitor and uses thereof

The present disclosure provides compounds of Formula (II) as disclosed herein, and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK inhibitors, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Quinolone derivatives as fibroblast growth factor inhibitors

Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

Inhibitors of Bruton's tyrosine kinase

Growing community of inventors

San Mateo, CA, United States of America

Erik J Verner